Bladder News and Research

RSS

NovaShunt raises Series B financing for CHF 23.7 million

NovaShunt AG, a private Swiss medical device company with innovative fluid management technologies, announced today that it has raised CHF 23.7 million in a Series B preferred share financing round co-led by BioMedInvest AG, Entrepreneurs Fund and Capricorn Health-tech Fund.

9 Mar 2011

Lab made urinary tube going strong after six years of transplant

In a scientific breakthrough, five boys who were unable to urinate due to pelvic injury were cured for up to six years after getting new lab-grown urethras or urinary tubes that connect with the bladder. This breakthrough comes from Wake Forest University researcher Anthony Atala. It was in 2006 that the team reported the first successful implantation of lab-grown urinary bladders into humans. Today six years after the operation all of the boys continue to do well, with normal or near-normal urinary flow. The boy first treated is now 16 years old and received his lab-grown urethra over six years ago.

8 Mar 2011

New advance in tissue engineering

Researchers at the Institute for Regenerative Medicine at Wake Forest University Baptist Medical Center and colleagues reported today on a new advance in tissue engineering.

8 Mar 2011

New promising detection technology identifies cancer cells early

Yesterday's Wall Street Journal (March 1) published a lead article on page D1 entitled "Researchers Create Better Ways To Spot Cancer Cells", which described the research by Dr. Edward R. Flynn, of Senior Scientific LLC. The article was authored by Shirley S. Wang.

4 Mar 2011

BCAN to host new forum on March 12 to raise awareness about bladder cancer

Bladder cancer is the fifth most commonly diagnosed cancer, and there are more than 600,000 survivors in the United States, yet most people know nothing about it.

4 Mar 2011

Allergan initiates AGN-214868 Phase II trials in post herpetic neuralgia and overactive bladder

Syntaxin, a biotechnology company developing novel biopharmaceuticals to control cell secretion, today announces its partner Allergan, Inc has initiated two Phase II trials to evaluate the safety and efficacy of its re-targeted endopeptidase drug candidate AGN-214868. The Phase II trials will be focused on patients with post herpetic neuralgia (PHN) and overactive bladder.

2 Mar 2011

TCD announces first patient treated in its TCD-717 Phase I trial

Traslational Cancer Drugs Pharma, S.L. (“TCD”) announced today that the first patient was treated on Friday the 18th of February with TCD-717 in a Phase I study performed in patients with advanced solid tumors. TCD-717 is a first-in-class, small molecule that precisely inhibits Choline Kinase Alpha, an enzyme heavily involved in the carcinogenic process. A total of 30 patients are planned to be treated in the trial, which will be conducted in accordance with FDA approval, in two leading medical centers in the U.S. The Principal Investigators are Dr. Julie Brahmer at the Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Hospital in Baltimore; and Dr. Patricia LoRusso at the Barbara Ann Karmanos Cancer Institute in Detroit.

28 Feb 2011

Aeterna to present two novel anticancer compounds at Bio Partnering North America conference

Aeterna Zentaris Inc. today announced that its Vice President, Alliance Management and Intellectual Property, Eckhard Guenther, Ph.D., will make a presentation on two of the Company's novel anticancer compounds, AEZS-108 and AEZS-129, at Bio Partnering North America on Monday, February 28, 2011, at 4 p.m. in the West Meeting Room 218, of the Vancouver Convention Center in Vancouver, Canada.

23 Feb 2011

Scientists identify new cellular mechanism underlying hydronephrosis

One of the most common congenital defects in humans - it is detected in approximately 0.5% of fetuses analyzed by routine antenatal sonography - is a kidney abnormality known as hydronephrosis. Hydronephrosis arises because the flow of urine from the kidney to the bladder is impeded.

21 Feb 2011

Predictive to present results on development of real-time multiplexed PCR FGFR3 assay at ASCO 2011

Predictive Biosciences today announced that the Company will be presenting results on the development of a real-time multiplexed PCR assay for detection of FGFR3 mutations in urine and tissue at the American Society of Clinical Oncology (ASCO) 2011 Genitourinary Cancers Symposium being held February 17 - 19 in Orlando, Florida. Results will also focus on the application of the assay which is currently being used in Predictive's first commercial molecular grading product, the CertNDxTM Molecular Grading Assay.

19 Feb 2011

Canadian Cancer Society praises new, enhanced cigarette package warnings

Today, Health Canada released a set of new picture health warnings for cigarette and little cigar packages. The new labels include 16 warnings that will cover 75 per cent of the package front and back, eight additional messages to be printed inside the package (or on an insert), and four toxic emission messages for the side panel.

19 Feb 2011

Urocidin Phase III non-muscle-invasive bladder cancer trial interim results to be presented at EAU, AUA conferences

Endo Pharmaceuticals and Bioniche Life Sciences Inc. today announced plans for peer-reviewed presentation of interim efficacy and safety results from the first Phase III trial of the intravesical formulation of Mycobacterial cell wall-DNA complex (MCC), known as Urocidin™ or EN3348.

18 Feb 2011

Endo Pharmaceuticals, Bioniche announce first patient enrollment in Urocidin second Phase III trial

Endo Pharmaceuticals and Bioniche Life Sciences Inc., today announced enrollment of the first patient in the second Phase III clinical trial of Urocidin.

16 Feb 2011

Study: High bilirubin levels within normal range linked with reduced risk of respiratory diseases

An analysis of data including more than 500,000 adults indicates that levels in the blood of bilirubin in the normal range but relatively higher were associated with a reduced risk of lung cancer, chronic obstructive pulmonary disease and all-cause death, according to a study in the February 16 issue of JAMA.

15 Feb 2011

FDA waives NDA filing fee for Antares' Anturol NDA

Antares Pharma, Inc. today announced the receipt from the U.S. Food and Drug Administration (FDA) of a waiver, on February 8, 2011, for the $1,500,000 New Drug Application (NDA) filing fee for Anturol® Gel for overactive bladder (OAB).

14 Feb 2011

Seven-year study demonstrates clear benefits of fetal surgery to treat spina bifida in babies

Results of a landmark, seven-year National Institutes of Health-funded trial, Management of Myelomeningocele Study (MOMS), demonstrate clear benefit for babies who undergo fetal surgery to treat spina bifida, the most common birth defect in the central nervous system.

11 Feb 2011

New study: Fetal surgery for spina bifida greatly improves child's mobility

Performing delicate surgery in the womb, months before birth, can substantially improve outcomes for children with a common, disabling birth defect of the spine. Experts at The Children's Hospital of Philadelphia co-led a new landmark study showing that fetal surgery for spina bifida greatly reduces the need to divert fluid from the brain, improves mobility and improves the chances that a child will be able to walk independently.

9 Feb 2011

American Cancer Society report released on World Cancer Day

A new American Cancer Society report says cancers associated with lifestyles and behaviors related to economic development, including lung, breast, and colorectal cancers, will continue to rise in developing countries if preventive measures are not widely applied. The finding comes from the second edition of Global Cancer Facts & Figures and its academic publication, Global Cancer Statistics, published in CA: A Cancer Journal for Clinicians.

4 Feb 2011

U.S. Patent Office issues Notice of Allowance to Antigen Express AE37 cancer vaccine

Generex Biotechnology Corporation, together with its wholly-owned immunotherapeutic vaccines subsidiary, Antigen Express, announced today that Antigen Express has received a Notice of Allowance from the United States Patent Office relating to an application making augmentative pharmaceutical composition claims for the Antigen Express AE37 immunotherapeutic cancer vaccine.